This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutDosingEfficacy & SafetyEfficacy & SafetyStudy DesignEfficacySafety ProfileSupport Your PatientSupport Your PatientEventsMaterialsAccess and Patient SupportSpecialty PharmaciesDownloadable Resources and Publications
Full Prescribing Information, including BOXED WARNINGPatient SiteIndication
Study DesignTrial Structure​​​​​​​BRIGHT AML 1003 was a randomized, phase 2 study1,2DAURISMO (glasdegib) was studied in older, difficult-to-treat adult patients with newly diagnosed AML who were not eligible for intensive chemotherapy (N=115)1-3

Patients were considered difficult to treat based on the eligibility criteria below.

  • Patients were stratified by cytogenetic risk (good/intermediate or poor)1
  • Treatment was continued until disease progression or unacceptable toxicity1
  • To assess response, BM samples were collected at screening, on day 1 of cycle 3 and every third cycle, within 14 days of achieving initial hematologic recovery in the peripheral blood, at the end of treatment, and at investigator discretion2​​​​​​​
AML patients included de novo AML and sAML. sAML was defined in the trial as AML evolving from MDS or another AHD, and AML occurring after previous cytotoxic therapy or radiation.2Response assessments included complete response (CR), complete response with incomplete blood count recovery (CRi), cytogenetic complete response, molecular complete response, morphologic leukemia-free state (MLFS), minor response (MR), partial remission (PR), partial remission with incomplete blood count recovery (PRi), and stable disease (SD).2AHD=antecedent hematologic disorder; BM=bone marrow; ECOG PS=Eastern Cooperative Oncology Group performance status; LDAC=low-dose cytarabine; LVEF=left ventricular ejection fraction; MDS=myelodysplastic syndrome; OS=overall survival; sAML=secondary AML.The majority (65%) of patients met ≥2 criteria for nonintensive treatment at baseline1,2​​​​​​​Medical Dictionary for Regulatory Activities preferred terms for severe cardiac disease were determined by study team review of medical history. Patients may have had multiple applicable terms for severe cardiac disease (eg, LVEF <45% by multigated acquisition scan or echocardiography at screening).2Patient characteristics​​​​​​​Patients in the BRIGHT AML 1003 trial had characteristics that made them difficult to treat1-3Key patient characteristics in the DAURISMO (glasdegib) + LDAC arm
  • The majority (61%) of patients were ≥75 years old
  • 51% had sAML
  • Approximately 28% of patients with sAML were treated with a prior HMA for MDS
  • 53% had an ECOG PS of 2
  • 32% had adverse-risk disease
  • 66% had severe cardiac disease (LVEF <45%)
  • 19% had serum creatinine >1.3 mg/dL
  • 22% had baseline bone marrow blast count <30%​​​​​​​
Baseline ECOG PS and baseline BM blast count were not reported for 1 patient each in the DAURISMO + LDAC arm.​​​​​​​Medical Dictionary for Regulatory Activities preferred terms for severe cardiac disease were determined by study team review of medical history. Patients may have had multiple applicable terms for severe cardiac disease (eg, LVEF <45% by multigated acquisition scan or echocardiography at screening).2​​​​​ELN=European LeukemiaNet; HMA=hypomethylating agent.​​​​​​​References:Daurismo [Prescribing Information]. New York, NY: Pfizer Inc.; 2020.Data on file. Pfizer Inc., New York, NY.
Klepin HD. Elderly acute myeloid leukemia: assessing risk. Curr Hematol Malig Rep. 2015;10(2):118-125.
Efficacy

The efficacy of DAURISMO + LDAC was established on the basis of overall survival 
See the overall survival data
Loading
Safety Profile

The safety profile of DAURISMO + LDAC was established in older patients not eligible for intensive chemotherapy

Find out moreLoading
Mechanism of Action

DAURISMO is the first hedgehog pathway inhibitor in the treatment of AML 

Review the MOALoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-GDG-USA-0274
You are now leaving Pfizer
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
INDICATION DAURISMOTM (glasdegib) is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Important Safety Information

WARNING: EMBRYO-FETAL TOXICITY: DAURISMO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. DAURISMO is embryotoxic, fetotoxic, and teratogenic in animals. Conduct pregnancy testing in females of reproductive potential prior to initiation of DAURISMO treatment. Advise females of reproductive potential to use effective contraception during treatment with DAURISMO and for at least 30 days after the last dose. Advise males of the potential risk of DAURISMO exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with DAURISMO and for at least 30 days after the last dose to avoid potential drug exposure.

Blood Donation: Advise patients not to donate blood or blood products while taking DAURISMO and for at least 30 days after the last dose, because their blood or blood products might be given to a female of reproductive potential.

QTc Interval Prolongation: Patients treated with DAURISMO can develop QTc prolongation and ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia. Of the 98 evaluable patients treated with DAURISMO 100 mg in combination with low-dose cytarabine in the clinical trial, 5% were found to have a QTc interval greater than 500 ms and 4% of patients had an increase from baseline QTc greater than 60 ms. The clinical trial excluded patients with baseline QTc of greater than 470 ms or with a history of long QT syndrome or uncontrolled cardiovascular disease. Monitor electrocardiograms (ECGs) and electrolytes. Concomitant use of DAURISMO with drugs known to prolong the QTc interval and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. In patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring is recommended. Interrupt DAURISMO if QTc interval is >500 ms and discontinue permanently for patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.

Adverse Reactions: Most common adverse reactions associated with DAURISMO (incidence ≥20%) were anemia (43%), fatigue (36%), hemorrhage (36%), febrile neutropenia (31%), musculoskeletal pain (30%), edema (30%), thrombocytopenia (30%), nausea (29%), dyspnea (23%), decreased appetite (21%), dysgeusia (21%), mucositis (21%), constipation (20%), and rash (20%).

Drug Interactions: Co-administration with strong CYP3A4 inhibitors increased DAURISMO plasma concentrations, which may increase the risk of adverse reactions including QTc interval prolongation. Consider alternative therapies that are not strong CYP3A4 inhibitors during treatment with DAURISMO and monitor patients for increased risk of adverse reactions including QTc interval prolongation. Strong and moderate CYP3A4 inducers should be avoided due to decreased DAURISMO plasma concentrations, which may reduce efficacy. If concomitant use of moderate CYP3A4 inducers cannot be avoided, increase the DAURISMO dosage to 200 mg once daily (if the patient is taking 100 mg) and 100 mg once daily (if the patient is taking 50 mg) as tolerated. Co-administration of DAURISMO with QTc-prolonging drugs may increase the risk of QTc interval prolongation. Avoid co-administration of QTc-prolonging drugs with DAURISMO or replace with alternative therapies. If co-administration of a QTc-prolonging drug is unavoidable, monitor patients for increased risk of QTc interval prolongation.

Lactation: Because of the potential for serious adverse reactions from DAURISMO in a breastfed child, advise women who are taking DAURISMO not to breastfeed or provide breast milk to infants or children during treatment and for at least 30 days after the last dose.

Renal Impairment: No dosage modification is recommended for patients with mild to severe renal impairment. Monitor patients with severe renal impairment (eGFR 15 to 29 mL/min) for increased risk of adverse reactions, including QTc interval prolongation, due to increased glasdegib concentrations.

Indication DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.